Trials / Completed
CompletedNCT00201786
Phase II Trial of Pentostatin in Steroid Refractory Acute Graft Versus Host Disease
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- Ohio State University Comprehensive Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the response rate to treatment with pentostatin in steroid-refractory acute graft versus host disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pentostatin | Pentostatin is given at a dose of 1.5 mg/m2/day IV x 3 consecutive days. Each IV infusion of pentostatin will be administered over 20-30 minutes in 100-250 ml of D5W or NS. To prevent nephrotoxicity, patients will also receive 500 ml normal saline as pre- and post drug hydration (total 1000 ml). |
Timeline
- Start date
- 2003-07-01
- Primary completion
- 2007-10-01
- Completion
- 2013-07-01
- First posted
- 2005-09-20
- Last updated
- 2016-04-27
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00201786. Inclusion in this directory is not an endorsement.